The Pharmacology of Imepitoin: The First Partial Benzodiazepine Receptor Agonist Developed for the Treatment of Epilepsy

@article{Rundfeldt2013ThePO,
  title={The Pharmacology of Imepitoin: The First Partial Benzodiazepine Receptor Agonist Developed for the Treatment of Epilepsy},
  author={C. Rundfeldt and W. L{\"o}scher},
  journal={CNS Drugs},
  year={2013},
  volume={28},
  pages={29-43}
}
  • C. Rundfeldt, W. Löscher
  • Published 2013
  • Medicine
  • CNS Drugs
  • Although benzodiazepines (BZDs) offer a wide spectrum of antiepileptic activity against diverse types of epileptic seizures, their use in the treatment of epilepsy is limited because of adverse effects, loss of efficacy (tolerance), and development of physical and psychological dependence. BZDs act as positive allosteric modulators of the inhibitory neurotransmitter GABA by binding to the BZD recognition site (“BZD receptor”) of the GABAA receptor. Traditional BZDs such as diazepam or… CONTINUE READING
    GABA Receptors: Pharmacological Potential and Pitfalls.
    • 38
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 69 REFERENCES
    Anxioselective anxiolytics: on a quest for the Holy Grail.
    • 57
    • Highly Influential